Year: 2025

Studio City International Holdings Limited Announces Unaudited Third Quarter 2025 Earnings

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

MACAU, Nov. 06, 2025 (GLOBE NEWSWIRE) — Studio City International Holdings Limited (NYSE: MSC) (“Studio City” or the “Company”), a world-class integrated resort located in Cotai, Macau, today reported its unaudited financial results for the third quarter of 2025. Total operating revenues for the third quarter of 2025 were US$182.5 million, compared with US$174.6 million in the third quarter of 2024. The increase was primarily attributable to better performance in mass market operations leading to an increase in revenue from casino contract. Studio City Casino generated gross gaming revenues of US$344.4 million and US$335.5 million for the third quarters of 2025 and 2024, respectively. Mass market table games drop was US$942.5 million in the third quarter of 2025, compared with US$912.9 million in the third quarter of 2024 and hold...

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care. Patient recruitment and enrollment in progress for Phase 1/2 STAND study in chronic neuropathic pain following activation of two clinical sites. Expect to dose first patient in the coming months. Held productive interaction with Medicines and Healthcare products Regulatory Agency (MHRA) to...

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion

Written by Customer Service on November 6, 2025. Posted in Public Companies.

Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its CY 2026 Medicare Physician Fee Schedule Final Rule confirming continued reimbursement for excimer laser treatments under CPT® codes 96920, 96921, and 96922, while recognizing the upcoming expansion of CPT code descriptors to include inflammatory and autoimmune skin conditions beyond psoriasis—effective January 1, 2027. In the Final Rule, CMS recognized the excimer laser as a well-established...

Skyharbour’s Partner Mustang Energy Corp. Announces Results of TDEM Survey Over the 914W Property

Written by Customer Service on November 6, 2025. Posted in Public Companies.

Vancouver, BC, Nov. 06, 2025 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”) is pleased to announce that partner company Mustang Energy Corp. (“Mustang”) received the results of a high resolution HTDEM survey at the 914W Uranium Project (the “Project”), totaling 136 line-kms. The Project has road access and is in a prospective region known for its mineral potential south of the Athabasca Basin. The 914W TDEM survey successfully defined a well-developed conductive zone within the project. The geometry and strength of the anomaly are consistent with graphitic basement rocks or fault-bound alteration zones, both favorable for unconformity-type uranium mineralization. Mustang Energy may acquire a 75% interest in the Project by issuing common shares having an...

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Written by Customer Service on November 6, 2025. Posted in Public Companies.

– Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines – – New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory access pathway for Solid to work directly with the UK’s National Health System (NHS), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and health technology assessment (HTA) bodies: the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Therapeutics and Toxicology Centre (AWTTC) – – Innovation Passport supports the potential for SGT-003 to become the first-to-market gene therapy in the UK for Duchenne muscular dystrophy – CHARLESTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Solid...

Greenridge Exploration Highlights Successful Results of Airborne Electromagnetic and Radiometric Survey for the Flying Vee Project

Written by Customer Service on November 6, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3 | OTCQB: GXPLF), is pleased to announce the results of a helicopter-borne time-domain electromagnetic and radiometric survey (collectively, the “Survey”) from the Flying Vee Project (“Flying Vee”, or the “Project”). Axiom Exploration Group Ltd. of Saskatoon, Saskatchewan, Canada (“Axiom”) performed a high-resolution Xcite™ survey at the Project in Q3 2025. The 2025 Survey successfully improved the interpretation of known conductive structural trends on the Project that could be prospective for hosting sulphide mineralization, including critical metals such as nickel-copper-cobalt, and gold. Russell Starr, Chief Executive Officer of the Company stated, “The results of the Flying Vee...

SharpLink to Host Third Quarter 2025 Financial Results Conference Call and Webcast on November 13, 2025 at 8:30 A.M. E.T.

Written by Customer Service on November 6, 2025. Posted in Public Companies.

MINNEAPOLIS, MN, Nov. 06, 2025 (GLOBE NEWSWIRE) — SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the world’s largest corporate holders of Ether (“ETH”) and prominent industry advocate of Ethereum adoption, today announced that the Company will host a conference call on Thursday, November 13, 2025 at 8:30 A.M. Eastern Time to discuss its financial and operating results for the three and nine months ended September 30, 2025. The Company will release its financial results in a press release prior to the call. SharpLink’s executive team will host the conference call, followed by a question-and-answer period. The conference call details are as follows: Date: Thursday, November 13, 2025Time: 8:30 A.M. Eastern TimeToll-free dial-in number: (877) 407-2988 International dial-in number: (201) 389-0923 Webcast:...

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Written by Customer Service on November 6, 2025. Posted in Public Companies.

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug’s Direct Macrophage-Mediated Mechanisms that Are Key to PSC Disease Progression— —All Three Presentations Have Been Designated as Posters of Distinction— TEL AVIV, Israel and WASHINGTON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that abstracts that highlight new clinical data from the nebokitug Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) will be presented on November 10, 2025, at the American Association for...

Enphase Energy IQ8 Microinverters Power Solar Projects at Gas Stations Worldwide

Written by Customer Service on November 6, 2025. Posted in Public Companies.

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced that its IQ8™ Microinverters have been selected for gas station solar projects around the world, helping businesses deploy clean, reliable energy in some of the most safety-critical commercial environments. Enphase microinverters are uniquely suited to gas station installations thanks to their AC-based system architecture, which eliminates the risk of dangerous high-voltage DC wiring and potential arc-fault fires. Built-in Rapid Shutdown capabilities ensure automatic system shutdown in emergencies, while a NEMA 6 rating allows for reliable performance in harsh weather conditions. These features, combined...

Dentsply Sirona Reports Third Quarter 2025 Results

Written by Customer Service on November 6, 2025. Posted in Public Companies.

Dentsply Sirona Reports Third Quarter 2025 ResultsNet sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buy GAAP gross margin of 48.8%, GAAP net loss per share of ($2.14) Adjusted gross margin of 52.6%, adjusted EBITDA margin of 18.4%, adjusted EPS of $0.37 Revised FY25 outlookExecuting its Return-to-Growth action plan to drive improved performance and deliver sustained, profitable growth Provides leadership updates to support transformation strategyCHARLOTTE, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the third quarter of 2025 and introduced its Return-to-Growth action plan, a comprehensive...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals